• Users Online: 34
  • Print this page
  • Email this page
Export selected to
Endnote
Reference Manager
Procite
Medlars Format
RefWorks Format
BibTex Format
  Access statistics : Table of Contents
   2022| July-September  | Volume 5 | Issue 3  
    Online since October 13, 2022

 
 
  Archives   Previous Issue   Most popular articles   Most cited articles
 
Show all abstracts  Show selected abstracts  Export selected to
  Viewed PDF Cited
REVIEWS
Research progress of drug resistance mechanisms to temozolomide in glioblastoma: A narrative review
Allen Lu
July-September 2022, 5(3):81-86
DOI:10.4103/glioma.glioma_24_22  
  1,406 150 -
Progress on TTFields combined with other therapies for glioblastoma treatment: A narrative review
Yong Cao, Haibin Wu, Bin Tang, Meihua Li, Yilv Wan, Jian Duan, Jiang Xu
July-September 2022, 5(3):90-98
DOI:10.4103/glioma.glioma_12_22  
  1,422 93 -
Associations of O6-methylguanine-DNA methyltransferase promoter methylation status with age and 1p/19q codeletion status in isocitrate dehydrogenase mutation gliomas based on an Asian cohort: A narrative review
Xu Wang, Mingzhi Han
July-September 2022, 5(3):87-89
DOI:10.4103/glioma.glioma_25_22  
  1,157 88 -
CASE REPORTS
WHO grade III diffuse astrocytic glioma in a 35-year-old male
Rong Du, Huandong Liu, Guoqing Yi, Huilin Cheng, Ping Liang
July-September 2022, 5(3):107-109
DOI:10.4103/glioma.glioma_26_22  
  698 72 -
Brain metastases treated with CyberKnife and TomoTherapy: A report of three cases
Li Zhu, Ying Li, Xiangyu Kong, Anna Mu, Ye Zhang, Liping Chen, Xia Li
July-September 2022, 5(3):99-106
DOI:10.4103/glioma.glioma_23_22  
  672 77 -
CORRIGENDUM
Corrigendum: Initial report of a clinical trial evaluating the safety and efficiency of neoadjuvant camrelizumab and apatinib in patients with recurrent high-grade gliomas: A prospective, phase II, single-arm study

July-September 2022, 5(3):110-111
DOI:10.4103/glioma.glioma_19_22  
  410 48 -